Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
Aethlon Medical (Nasdaq: AEMD) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. It said it dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia and cited preliminary biomarker signals for its Hemopurifier. Cash was about $4.9M; it raised about $4.0M gross via a stock offering.
How this was made
The 30-second read
Why it matters
This PR combines (1) quarterly financials and cash runway, (2) a subsequent equity raise, and (3) incremental clinical and translational science updates (final cohort dosing in Australia, preliminary biomarker trends, and a Long COVID manuscript acceptance).
Market read
Traders likely weigh dilution and cash runway against incremental trial progress and supportive translational evidence tied to Hemopurifier binding.
What to watch
Cash is only ~$4.9M at quarter-end; even with the stated 12-month runway, any slower enrollment or additional financing needs could dominate the stock’s next catalyst.
Background
Aethlon is a clinical-stage company developing the Hemopurifier, an investigational extracorporeal device aimed at removing enveloped viruses and tumor-derived extracellular vesicles.
Ticker impact
Aethlon reported Q1 FY2027 results, disclosed $4.0M follow-on stock offering, and said the Hemopurifier Phase 1 oncology trial dosed the final cohort participant in Australia.
Moderate upside bias possible on risk-on sentiment, but dilution and early clinical nature likely cap the move.
The release adds concrete, time-sensitive items: quarterly cash balance, a subsequent public offering, and a specific clinical dosing milestone. However, it does not provide efficacy endpoints or safety data, so conviction is limited.
Market effects
Adds another data point for extracorporeal immunotherapy and EV-removal platforms, but without new efficacy endpoints it is unlikely to re-rate the whole sector.
Australia trial dosing milestone may support local clinical-trial sentiment, but impact is company-specific.
Long COVID manuscript acceptance and Hemopurifier binding claim may modestly strengthen global interest in EV-targeting approaches.
Counterpoint
The most actionable item is dilution risk from the $4.0M offering, while the clinical update remains preliminary with no quantified outcomes.
Key entities
- companyAethlon Medical, Inc.
Nasdaq-listed clinical-stage therapeutic company advancing the Hemopurifier program.
- productHemopurifier®
Investigational extracorporeal device designed to remove enveloped viruses and tumor-derived extracellular vesicles using affinity binding.
- clinical_programPhase 1 oncology study (Australia)
Company’s Phase 1 oncology trial where the first participant was dosed in the third and final cohort.
- financingPublic offering of common stock
Subsequent to quarter-end, Aethlon raised approximately $4.0M gross proceeds via a public offering.
